{"id":11388917,"date":"2025-12-25T21:49:42","date_gmt":"2025-12-25T19:49:42","guid":{"rendered":"https:\/\/nostylelike.net\/?post_type=product&#038;p=11388917"},"modified":"2026-07-12T14:11:14","modified_gmt":"2026-07-12T11:11:14","slug":"evrysdi-risdiplam-for-spinal-muscular","status":"publish","type":"product","link":"https:\/\/nostylelike.net\/en\/product\/evrysdi-risdiplam-for-spinal-muscular\/","title":{"rendered":"Evrysdi Treatment for Spinal Muscular Atrophy"},"content":{"rendered":"<p><strong>Evrysdi risdiplam<\/strong> \u2014 Evrysdi Treatment for Spinal Muscular Atrophy is available now at No Style Like with fast delivery across Egypt.<\/p>\n<div dir=\"ltr\" style=\"text-align: left\">\n<h2 id=\"evrysdi\">Evrysdi Risdiplam \u2013 Spinal Muscular Atrophy Treatment | Complete Clinical Guide<\/h2>\n<div style=\"background: #f0f7ff;border-left: 4px solid #1a73e8;padding: 16px;border-radius: 6px\"><strong>Quick Answer:<\/strong> Evrysdi risdiplam is an <strong>FDA and EMA-approved oral disease-modifying treatment<\/strong> for Spinal Muscular Atrophy (SMA) Types 1, 2, and 3, approved for patients from 2 months of age through adulthood. It is the only oral at-home SMA therapy \u2014 a once-daily liquid or tablet requiring no hospital visits. Developed by Roche\/Genentech with PTC Therapeutics. <strong>Prescription only \u2014 treatment must be initiated and monitored by a neurologist or physician experienced in SMA.<\/strong><\/div>\n<div style=\"max-width: 560px;margin: 12px 0;font-family: system-ui,-apple-system,Segoe UI,Roboto,Arial;direction: ltr;text-align: left\">\n<table style=\"width: 100%;border-collapse: separate;border-spacing: 0;overflow: hidden;border: 1px solid #e5e7eb;border-radius: 12px\">\n<tbody>\n<tr>\n<th style=\"width: 42%;text-align: left;background: #fafafa;padding: 12px 14px;border-bottom: 1px solid #eee;font-weight: bold;color: #111\">Name<\/th>\n<td style=\"padding: 12px 14px;border-bottom: 1px solid #eee;color: #111\">Evrysdi (Risdiplam)<\/td>\n<\/tr>\n<tr>\n<th style=\"text-align: left;background: #fafafa;padding: 12px 14px;border-bottom: 1px solid #eee;font-weight: bold;color: #111\">Manufacturer<\/th>\n<td style=\"padding: 12px 14px;border-bottom: 1px solid #eee;color: #111\">Roche \/ Genentech (with PTC Therapeutics)<\/td>\n<\/tr>\n<tr>\n<th style=\"text-align: left;background: #fafafa;padding: 12px 14px;border-bottom: 1px solid #eee;font-weight: bold;color: #111\">Active Ingredient<\/th>\n<td style=\"padding: 12px 14px;border-bottom: 1px solid #eee;color: #111\">Risdiplam \u2014 SMN2 pre-mRNA splicing modifier<\/td>\n<\/tr>\n<tr>\n<th style=\"text-align: left;background: #fafafa;padding: 12px 14px;border-bottom: 1px solid #eee;font-weight: bold;color: #111\">Drug Class<\/th>\n<td style=\"padding: 12px 14px;border-bottom: 1px solid #eee;color: #111\">SMN2 splicing modifier (small molecule)<\/td>\n<\/tr>\n<tr>\n<th style=\"text-align: left;background: #fafafa;padding: 12px 14px;border-bottom: 1px solid #eee;font-weight: bold;color: #111\">Available Forms<\/th>\n<td style=\"padding: 12px 14px;border-bottom: 1px solid #eee;color: #111\">Oral solution 0.75 mg\/mL | Tablet 5 mg<\/td>\n<\/tr>\n<tr>\n<th style=\"text-align: left;background: #fafafa;padding: 12px 14px;border-bottom: 1px solid #eee;font-weight: bold;color: #111\">Approved For<\/th>\n<td style=\"padding: 12px 14px;border-bottom: 1px solid #eee;color: #111\">SMA Types 1, 2, 3 \u2014 from 2 months of age<\/td>\n<\/tr>\n<tr>\n<th style=\"text-align: left;background: #fafafa;padding: 12px 14px;border-bottom: 1px solid #eee;font-weight: bold;color: #111\">Regulatory Status<\/th>\n<td style=\"padding: 12px 14px;border-bottom: 1px solid #eee;color: #111\">FDA approved Aug 2020 | EMA approved Mar 2021<\/td>\n<\/tr>\n<tr>\n<th style=\"text-align: left;background: #fafafa;padding: 12px 14px;font-weight: bold;color: #111;border-bottom: 0;border-top: 1px solid #eee\">Prescription Status<\/th>\n<td style=\"padding: 12px 14px;color: #111;border-bottom: 0\">Prescription only \u2014 physician-directed dosing<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div style=\"max-width: 560px;margin: 12px 0;padding: 14px;background: #f9f9f9;border: 1px solid #e5e7eb;border-radius: 12px;color: #111;line-height: 1.6\">Evrysdi (risdiplam) is the first and only oral, at-home treatment for SMA approved for patients from 2 months through adulthood. It modifies SMN2 gene splicing to produce functional SMN protein, slowing disease progression. Prescription only \u2014 dose determined by weight and age under specialist supervision.<\/div>\n<h2>Table of Contents<\/h2>\n<ul>\n<li><a href=\"#what-is\">What Is Evrysdi?<\/a><\/li>\n<li><a href=\"#mechanism\">How Does It Work?<\/a><\/li>\n<li><a href=\"#indications\">Approved Indications<\/a><\/li>\n<li><a href=\"#dosage\">Dosage &amp; Administration<\/a><\/li>\n<li><a href=\"#contraindications\">Contraindications<\/a><\/li>\n<li><a href=\"#side-effects\">Side Effects<\/a><\/li>\n<li><a href=\"#monitoring\">Monitoring Requirements<\/a><\/li>\n<li><a href=\"#interactions\">Drug Interactions<\/a><\/li>\n<li><a href=\"#storage\">Storage &amp; Handling<\/a><\/li>\n<li><a href=\"#expert-tip\">NSL Expert Note<\/a><\/li>\n<li><a href=\"#faq\">FAQ<\/a><\/li>\n<\/ul>\n<h2 id=\"what-is\">What Is Evrysdi Risdiplam?<\/h2>\n<p>Evrysdi risdiplam \u2014 the oral risdiplam therapy \u2014 is a small-molecule SMN2 splicing modifier \u2014 the active treatment in this oral SMA therapy. SMA is caused by mutations in the SMN1 gene, leading to deficiency of survival motor neuron (SMN) protein \u2014 essential for motor neuron health. Without adequate SMN protein, motor neurons degenerate, causing progressive muscle weakness and loss of function.<\/p>\n<p>Risdiplam is a systemic treatment that crosses the blood-brain barrier and acts throughout the body, including the central nervous system. Unlike spinal injections (nusinersen\/Spinraza) or gene therapy (onasemnogene\/Zolgensma), Evrysdi is taken orally at home \u2014 a critical advantage for long-term management.<\/p>\n<h2 id=\"mechanism\">How Does Evrysdi Risdiplam Work?<\/h2>\n<p>The SMN2 gene is a backup gene in all SMA patients. Normally, SMN2 produces mostly truncated, non-functional SMN protein due to skipping of exon 7 during splicing. Risdiplam binds to SMN2 pre-mRNA and modifies its splicing \u2014 increasing inclusion of exon 7 \u2014 so that SMN2 produces more full-length, functional SMN protein. Because risdiplam is orally administered and distributed systemically, it increases SMN protein in both the CNS and peripheral tissues.<\/p>\n<h2 id=\"indications\">Evrysdi Risdiplam \u2013 Approved Indications<\/h2>\n<ul>\n<li><strong>SMA Type 1<\/strong> \u2014 infantile-onset, most severe; typically presents within first 6 months<\/li>\n<li><strong>SMA Type 2<\/strong> \u2014 intermediate; onset 6\u201318 months<\/li>\n<li><strong>SMA Type 3<\/strong> \u2014 milder; onset after 18 months, ambulatory patients<\/li>\n<li><strong>Pre-symptomatic SMA<\/strong> \u2014 patients with 1\u20134 SMN2 copies detected before symptom onset<\/li>\n<li>Patients <strong>from 2 months of age<\/strong> through adulthood<\/li>\n<\/ul>\n<h2 id=\"dosage\">Dosage &amp; Administration<\/h2>\n<div style=\"background: #fff4f4;border-left: 4px solid #d33;padding: 16px;border-radius: 6px\"><strong>Dosage is strictly physician-directed.<\/strong> Dose is calculated by age and body weight. Must not be self-adjusted. Administered once daily after a meal at approximately the same time each day.<\/div>\n<ul>\n<li>Infants 2 months to &lt;2 years: weight-based dosing<\/li>\n<li>Patients \u22652 years and adults: weight-based dosing with maximum caps<\/li>\n<li>Oral solution (0.75 mg\/mL): prepared by pharmacist, administered with calibrated syringe<\/li>\n<li>Tablets (5 mg): for patients who can swallow tablets<\/li>\n<\/ul>\n<h2 id=\"contraindications\">Contraindications<\/h2>\n<ul>\n<li>Known hypersensitivity to risdiplam or any excipient<\/li>\n<li>Pregnancy \u2014 fetotoxic risk confirmed in animal studies; effective contraception required<\/li>\n<li>Severe hepatic impairment \u2014 avoid use<\/li>\n<\/ul>\n<h2 id=\"side-effects\">Side Effects<\/h2>\n<table style=\"border-collapse: collapse;width: 100%\" border=\"1\" cellpadding=\"8\">\n<tbody>\n<tr>\n<th>SMA Type<\/th>\n<th>Common Side Effects<\/th>\n<\/tr>\n<tr>\n<td>SMA Type 1 (infants)<\/td>\n<td>Fever, upper respiratory infection, constipation, vomiting, rash, pneumonia<\/td>\n<\/tr>\n<tr>\n<td>SMA Types 2 &amp; 3<\/td>\n<td>Fever, diarrhea, rash, mouth sores, nasopharyngitis, headache<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Reproductive toxicity:<\/strong> Women of childbearing potential must use effective contraception during treatment and 1 month after final dose. Male patients: contraception required during treatment and 4 months after final dose.<\/p>\n<h2 id=\"monitoring\">Monitoring Requirements<\/h2>\n<ul>\n<li>Motor function assessments: CHOP INTEND (infants), HFMSE\/RULM (older patients)<\/li>\n<li>Hepatic function monitoring \u2014 especially in patients with pre-existing hepatic conditions<\/li>\n<li>Ophthalmological monitoring \u2014 based on animal study signals<\/li>\n<li>Regular weight measurements in growing children for dose adjustment<\/li>\n<li>Nutritional and respiratory monitoring per SMA multidisciplinary care standards<\/li>\n<\/ul>\n<h2 id=\"interactions\">Drug Interactions<\/h2>\n<table style=\"border-collapse: collapse;width: 100%\" border=\"1\" cellpadding=\"8\">\n<tbody>\n<tr>\n<th>Drug \/ Mechanism<\/th>\n<th>Consideration<\/th>\n<\/tr>\n<tr>\n<td>OAT1\/OAT3 substrates (methotrexate, tenofovir)<\/td>\n<td>Risdiplam inhibits these transporters; may increase substrate drug levels \u2014 monitor<\/td>\n<\/tr>\n<tr>\n<td>MATE1\/MATE2-K substrates<\/td>\n<td>Inhibition possible \u2014 monitor co-administered drugs eliminated by these pathways<\/td>\n<\/tr>\n<tr>\n<td>Strong CYP3A inhibitors<\/td>\n<td>May increase risdiplam exposure \u2014 monitor<\/td>\n<\/tr>\n<tr>\n<td>Other SMA treatments (nusinersen, gene therapy)<\/td>\n<td>Limited combination data \u2014 specialist decision required<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2 id=\"storage\">Storage &amp; Handling<\/h2>\n<ul>\n<li>Oral solution: refrigerate reconstituted solution (2\u20138\u00b0C); use within 64 days of reconstitution<\/li>\n<li>Tablets: store below 30\u00b0C; protect from moisture<\/li>\n<li>Use calibrated oral syringe provided; keep out of reach of children<\/li>\n<\/ul>\n<div style=\"background: #fff8e6;border-left: 4px solid #f5a623;padding: 16px;border-radius: 6px\">\n<p><strong>Dr. Abdallah Fouad, Clinical Nutrition Specialist:<\/strong> &#8220;Evrysdi represents a paradigm shift in SMA care \u2014 the ability to treat at home orally, across all ages, with systemic CNS and peripheral muscle distribution, changes everything for families. What I emphasize: the dose is strictly weight- and age-based, reconstitution must follow pharmacist instructions precisely, and monitoring \u2014 neurological and hepatic \u2014 is not optional. This is a lifelong treatment requiring ongoing specialist engagement.&#8221;<\/p>\n<\/div>\n<h2 id=\"faq\">Frequently Asked Questions<\/h2>\n<h3>What types of SMA does Evrysdi treat?<\/h3>\n<p>SMA Types 1, 2, and 3, plus pre-symptomatic SMA in patients from 2 months of age through adulthood.<\/p>\n<h3>How is Evrysdi different from Spinraza (nusinersen)?<\/h3>\n<p>Spinraza requires intrathecal injection every 4 months in hospital. Evrysdi is taken orally at home once daily \u2014 a major practical advantage for long-term management.<\/p>\n<h3>Does Evrysdi cure SMA?<\/h3>\n<p>No. It is disease-modifying, not curative. It increases SMN protein production, slowing progression and improving motor milestones \u2014 but does not restore already-lost motor neurons.<\/p>\n<h3>Can Evrysdi be combined with other SMA treatments?<\/h3>\n<p>Combination data is limited. The decision to combine treatments must be made by an SMA specialist.<\/p>\n<h3>Is Evrysdi safe during pregnancy?<\/h3>\n<p>No. Risdiplam is fetotoxic based on animal studies. Effective contraception is required during treatment and 1 month after the final dose.<\/p>\n<h3>What if a dose is missed?<\/h3>\n<p>Take the missed dose on the same day as soon as remembered. Do not double the dose the following day. Follow prescribing physician guidance.<\/p>\n<h3>How long does treatment last?<\/h3>\n<p>Evrysdi is an ongoing, long-term treatment. Discontinuation should only be considered under specialist guidance.<\/p>\n<h3>What monitoring is required?<\/h3>\n<p>Regular motor function assessments, hepatic function monitoring, weight-based dose adjustments as the child grows, and ophthalmological monitoring per specialist recommendation.<\/p>\n<h3>Can adults with SMA take Evrysdi?<\/h3>\n<p>Yes \u2014 Evrysdi is approved from 2 months of age through adulthood, one of the few SMA treatments spanning all age groups.<\/p>\n<h3>Where can I obtain Evrysdi in Egypt?<\/h3>\n<p>Evrysdi is available through No Style Like as an imported pharmaceutical. Prescription from an SMA specialist is required. Contact us for availability.<\/p>\n<p><strong>Related:<\/strong> <a href=\"\/?product_cat=prescription-medicines\">Prescription Medicines<\/a> \u00b7 <a href=\"\/?product_cat=vitamins-supplements\">Vitamins &amp; Supplements<\/a><\/p>\n<p><strong>Reviewed by:<\/strong> Dr. Abdallah Fouad, Clinical Nutrition Specialist \u2014 25+ years of experience<\/p>\n<p><em><strong><\/p>\n<h2>Why Choose Evrysdi risdiplam from No Style Like?<\/h2>\n<p>At No Style Like, we provide authentic Evrysdi risdiplam products with verified quality, competitive pricing, and expert guidance from Dr. Abdallah Fouad, Clinical Nutrition Specialist with 25+ years of experience.<\/p>\n<p>Medical Disclaimer:<\/strong> Evrysdi (risdiplam) is a prescription-only medicine for SMA. All treatment decisions must be made by a neurologist experienced in SMA. Educational content only. Source: <a href=\"https:\/\/medlineplus.gov\/druginfo\/meds\/a620050.html\" target=\"_blank\" rel=\"noopener nofollow\">MedlinePlus \u2013 Risdiplam<\/a> | <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/evrysdi\" target=\"_blank\" rel=\"noopener nofollow\">EMA \u2013 Evrysdi<\/a><\/em><\/p>\n<\/div>\n<p style=\"margin-top:20px\"><strong>You May Also Like:<\/strong> <a href=\"\/?product_cat=supplements\">Browse Supplements<\/a> | <a href=\"\/?product_cat=vitamins\">Vitamins<\/a> | <a href=\"\/?product_cat=personal-care\">Personal Care<\/a><\/p>\n<p><strong>Explore More:<\/strong> <a href=\"\/?product_cat=supplements\">All Supplements<\/a> | <a href=\"\/?product_cat=vitamins\">Vitamins<\/a> | <a href=\"\/?product_cat=personal-care\">Personal Care<\/a><\/p>\n<p><strong>References:<\/strong> <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/\" target=\"_blank\" rel=\"noopener nofollow\">PubMed Research Database<\/a> | <a href=\"https:\/\/www.who.int\/\" target=\"_blank\" rel=\"noopener nofollow\">World Health Organization<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<div style=\"max-width: 560px; margin: 12px 0; font-family: system-ui,-apple-system,Segoe UI,Roboto,Arial; direction: ltr; text-align: left;\">\n<table style=\"width: 100%; border-collapse: separate; border-spacing: 0; overflow: hidden; border: 1px solid #e5e7eb; border-radius: 12px;\">\n<tbody>\n<tr>\n<th style=\"width: 42%; text-align: left; background: #fafafa; padding: 12px 14px; border-bottom: 1px solid #eee; font-weight: bold; color: #111;\">Name<\/th>\n<td style=\"padding: 12px 14px; border-bottom: 1px solid #eee; color: #111;\">Evrysdi (Risdiplam)<\/td>\n<\/tr>\n<tr>\n<th style=\"text-align: left; background: #fafafa; padding: 12px 14px; border-bottom: 1px solid #eee; font-weight: bold; color: #111;\">Brand<\/th>\n<td style=\"padding: 12px 14px; border-bottom: 1px solid #eee; color: #111;\">Roche \/ Genentech (with PTC Therapeutics)<\/td>\n<\/tr>\n<tr>\n<th style=\"text-align: left; background: #fafafa; padding: 12px 14px; border-bottom: 1px solid #eee; font-weight: bold; color: #111;\">Strength<\/th>\n<td style=\"padding: 12px 14px; border-bottom: 1px solid #eee; color: #111;\">0.75 mg\/mL (powder for oral solution) | 5 mg tablet<\/td>\n<\/tr>\n<tr>\n<th style=\"text-align: left; background: #fafafa; padding: 12px 14px; border-bottom: 1px solid #eee; font-weight: bold; color: #111;\">Quantity \/ Size<\/th>\n<td style=\"padding: 12px 14px; border-bottom: 1px solid #eee; color: #111;\">1 bottle \u2014 powder for oral solution (reconstituted)<\/td>\n<\/tr>\n<tr>\n<th style=\"text-align: left; background: #fafafa; padding: 12px 14px; border-bottom: 1px solid #eee; font-weight: bold; color: #111;\">Form<\/th>\n<td style=\"padding: 12px 14px; border-bottom: 1px solid #eee; color: #111;\">Oral solution \/ Oral tablet<\/td>\n<\/tr>\n<tr>\n<th style=\"text-align: left; background: #fafafa; padding: 12px 14px; border-bottom: 1px solid #eee; font-weight: bold; color: #111;\">Appearance<\/th>\n<td style=\"padding: 12px 14px; border-bottom: 1px solid #eee; color: #111;\">Clear to slightly turbid, colorless to pale yellow solution<\/td>\n<\/tr>\n<tr>\n<th style=\"text-align: left; background: #fafafa; padding: 12px 14px; border-bottom: 1px solid #eee; font-weight: bold; color: #111;\">Expiry Date<\/th>\n<td style=\"padding: 12px 14px; border-bottom: 1px solid #eee; color: #111;\">Check packaging \u2014 store reconstituted solution up to 64 days (2\u20138\u00b0C)<\/td>\n<\/tr>\n<tr>\n<th style=\"text-align: left; background: #fafafa; padding: 12px 14px; border-bottom: 1px solid #eee; font-weight: bold; color: #111;\">Country of Origin<\/th>\n<td style=\"padding: 12px 14px; border-bottom: 1px solid #eee; color: #111;\">Switzerland (Roche)<\/td>\n<\/tr>\n<tr>\n<th style=\"text-align: left; background: #fafafa; padding: 12px 14px; font-weight: bold; color: #111; border-bottom: 0; border-top: 1px solid #eee;\">Product Code<\/th>\n<td style=\"padding: 12px 14px; color: #111; border-bottom: 0; border-top: 1px solid #eee;\">Evrysdi \u2014 FDA approved Aug 2020 | EMA approved Mar 2021<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div style=\"max-width: 560px; margin: 12px 0; padding: 14px; background: #f9f9f9; border: 1px solid #e5e7eb; border-radius: 12px; font-family: system-ui,-apple-system,Segoe UI,Roboto,Arial; direction: ltr; text-align: left; color: #111; line-height: 1.6;\">Evrysdi (risdiplam) is the first oral, at-home treatment for Spinal Muscular Atrophy (SMA) Types 1, 2 &amp; 3, approved for patients from 2 months of age. Once-daily oral solution or tablet \u2014 no hospital visits required. SMN2 splicing modifier. Prescription only \u2014 dose determined by weight and age under specialist supervision.<\/div>\n","protected":false},"featured_media":11388911,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[39214],"product_cat":[41996],"product_tag":[39569,39578,39577,39582,39589,39590,39591,39583,39579,39586,39588,39587,39585,39584],"class_list":["post-11388917","product","type-product","status-publish","has-post-thumbnail","product_brand-roche-en","product_cat-specialized-medicines","product_tag-evrysdi","product_tag-evrysdi-0-75-mg-ml","product_tag-evrysdi-risdiplam","product_tag-evrysdi-treatment","product_tag-genetic-neuromuscular-disease-treatment","product_tag-motor-neuron-disease-therapy","product_tag-oral-sma-medicine","product_tag-risdiplam-oral-solution","product_tag-roche-evrysdi","product_tag-sma-oral-medication","product_tag-sma-therapy-for-adults","product_tag-sma-therapy-for-children","product_tag-sma-treatment","product_tag-spinal-muscular-atrophy-treatment","first","onbackorder","sale","shipping-taxable","purchasable","product-type-simple"],"_links":{"self":[{"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product\/11388917","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/comments?post=11388917"}],"version-history":[{"count":10,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product\/11388917\/revisions"}],"predecessor-version":[{"id":11401755,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product\/11388917\/revisions\/11401755"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/media\/11388911"}],"wp:attachment":[{"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/media?parent=11388917"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product_brand?post=11388917"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product_cat?post=11388917"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product_tag?post=11388917"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}